A randomized, open label, multicenter phase 2 study, to evaluate the efficacy of sorafenib (So) in patients (pts) with metastatic renal cell carcinoma (mRCC) after a radical resection of the metastases: RESORT trial.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 4502-4502 ◽  
Author(s):  
Giuseppe Procopio ◽  
Francesco Cognetti ◽  
Rosalba Miceli ◽  
Michele Milella ◽  
Alessandra Mosca ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Radical Resection ◽  
Phase 2 ◽  
Open Label ◽  
Multicenter Phase ◽  
Phase 2 Study

A multicenter, open-label, single-arm, phase 2 study of the S1P inhibitor sonepcizumab (LT1009) in patients with previously treated metastatic renal cell carcinoma (mRCC).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. TPS4605-TPS4605
Author(s):  
Rupal Satish Bhatt ◽  
Sumanta Kumar Pal ◽  
Harry A. Drabkin ◽  
John D. Hainsworth ◽  
Andrew Dorr ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Study ◽  
Previously Treated

Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma

2016 ◽  
Vol 14 (4) ◽  
pp. 304-313.e6 ◽  
Author(s):  
Kathleen M. Mahoney ◽  
Susanna Jacobus ◽  
Rupal S. Bhatt ◽  
Jiaxi Song ◽  
Ingrid Carvo ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Phase 2 ◽  
Phase 2 Study

scholarly journals Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma

2020 ◽  
Vol 126 (1) ◽  
pp. 73-82 ◽  
Author(s):  
Sumanta K. Pal ◽  
David F. McDermott ◽  
Michael B. Atkins ◽  
Bernard Escudier ◽  
Brian I. Rini ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Patient Reported Outcomes ◽  
Phase 2 ◽  
Phase 2 Study ◽  
Patient Reported

scholarly journals Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

2015 ◽  
Vol 16 (15) ◽  
pp. 1473-1482 ◽  
Author(s):  
Robert J Motzer ◽  
Thomas E Hutson ◽  
Hilary Glen ◽  
M Dror Michaelson ◽  
Ana Molina ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Multicentre Trial ◽  
Phase 2 ◽  
Open Label
Sign in / Sign up

Export Citation Format

Share Document